Advertisement

3 Biotech

, 9:131 | Cite as

Erythropoietin protects neurons from apoptosis via activating PI3K/AKT and inhibiting Erk1/2 signaling pathway

  • Wei Si
  • Jianyi Wang
  • Mei Li
  • Hao Qu
  • Ran Gu
  • Rui Liu
  • Lu Wang
  • Shirong Li
  • Xiao HuEmail author
Original Article
  • 42 Downloads

Abstract

The aim of this study was to explore the neuroprotective effect and the underlying mechanism of erythropoietin (EPO) on the cortical neuronal cells insulted with oxygen and glucose deprivation (OGD). Different concentrations of EPO were used to determine the anti-apoptosis effect of EPO. In addition, PI3K inhibitor LY294002 and ERK1/2 inhibitor U0126 were added to explore the underlying mechanism of EPO. Cell apoptosis rate was measured by flow cytometry. The protein expression of Bax, Bcl-2, cleaved caspase-3, AKT, p-AKT, Erk1/2 and p-Erk1/2 wasmeasured by Western blot. Our results showed that EPO alleviates OGD-induced cell apoptosis in a dose-dependent manner; the neuroprotective effect of EPO was further confirmed by the fact that EPO treatment reversed the protein expression of cleaved caspase-3, as well as the Bcl-2/Bax ratio as compared with the OGD treatment. In the mechanism part, our results demonstrated that OGD and EPO nearly had no influence on the protein expression of AKT and Erk1/2 but altered the phosphorylation of them. Specifically, OGD decreased the expression of p-AKT and increased the expression of p-Erk1/2; while, EPO treatment reversed the expression of p-AKT and p-Erk1/2 as compared with OGD treatment. Interestingly, LY294002 decreased the expression of p-AKT and attenuated the neuroprotective effect of EPO; while, U0126 decreased the expression of p-Erk1/2 and enhanced the neuroprotective effect of EPO. Our study demonstrated that EPO protects neurons against apoptosis induced by OGD, which is closely related with activation of PI3K/AKT and inactivation of Erk1/2 signaling pathway.

Keywords

Erythropoietin Neuroprotective agents PI3K/AKT Erk1/2 

Notes

Acknowledgements

This study was sponsored by the Guizhou Science and Technology Cooperation Plan (Qian Ke He LH Zi [2014]7022).

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. Biggar P, Kim GH (2017) Treatment of renal anemia: erythropoiesis stimulating agents and beyond. Kidney Res Clin Pract 36:209–223.  https://doi.org/10.23876/j.krcp.2017.36.3.209 CrossRefPubMedPubMedCentralGoogle Scholar
  2. Castillo C et al (2017) Neuroprotective effect of a new variant of Epo nonhematopoietic against oxidative stress. Redox Biol 14:285–294.  https://doi.org/10.1016/j.redox.2017.09.010 CrossRefPubMedPubMedCentralGoogle Scholar
  3. Chen T et al (2017) Sirt1–Sirt3 axis regulates human blood–brain barrier permeability in response to ischemia. Redox Biol 14:229–236.  https://doi.org/10.1016/j.redox.2017.09.016 CrossRefPubMedPubMedCentralGoogle Scholar
  4. Ding J et al (2017) Neuroprotection and CD131/GDNF/AKT pathway of carbamylated erythropoietin in hypoxic neurons. Mol Neurobiol 54:5051–5060.  https://doi.org/10.1007/s12035-016-0022-0 CrossRefPubMedGoogle Scholar
  5. Garg BD, Sharma D, Bansal A (2017) Systematic review seeking erythropoietin role for neuroprotection in neonates with hypoxic ischemic encephalopathy: presently where do we stand. J Matern Fetal Neonatal Med.  https://doi.org/10.1080/14767058.2017.1366982 CrossRefPubMedGoogle Scholar
  6. Gong G et al (2014) Tetramethylpyrazine suppresses transient oxygen-glucose deprivation-induced connexin32 expression and cell apoptosis via the ERK1/2 and p38 MAPK pathway in cultured hippocampal neurons. PLoS One 9:e105944.  https://doi.org/10.1371/journal.pone.0105944 CrossRefPubMedPubMedCentralGoogle Scholar
  7. Grasso G, Alafaci C, Buemi M (2015) Erythropoietin in traumatic brain injury: an answer will come soon. World Neurosurg 84:1491–1492.  https://doi.org/10.1016/j.wneu.2015.05.056 CrossRefPubMedGoogle Scholar
  8. Guangyun Zhang XH, Ping Y, Wang J (2012) Establishment of in vitro model of neonatal mouse cortical neuronal injury induced by glutamate. J Neurol Anat 4:363–367Google Scholar
  9. Hernández CC, Burgos CF, Gajardo AH, Silva-Grecchi T, Gavilan J, Toledo JR, Fuentealba J (2017) Neuroprotective effects of erythropoietin on neurodegenerative and ischemic brain diseases: the role of erythropoietin receptor. Neural Regen Res 12:1381CrossRefGoogle Scholar
  10. Jeong JE, Park JH, Kim CS, Lee SL, Chung HL, Kim WT, Lee EJ (2017) Neuroprotective effects of erythropoietin against hypoxic injury via modulation of the mitogen-activated protein kinase pathway and apoptosis. Korean J Pediatr 60:181–188.  https://doi.org/10.3345/kjp.2017.60.6.181 CrossRefPubMedPubMedCentralGoogle Scholar
  11. Jia Y et al (2014) EPO-dependent activation of PI3K/Akt/FoxO3a signalling mediates neuroprotection in in vitro and in vivo models of Parkinson’s disease. J Mol Neurosci 53:117–124.  https://doi.org/10.1007/s12031-013-0208-0 CrossRefPubMedGoogle Scholar
  12. Li D-J, Li Y-H, Yuan H-B, Qu L-F, Wang P (2017) The novel exercise-induced hormone irisin protects against neuronal injury via activation of the Akt and ERK1/2 signaling pathways and contributes to the neuroprotection of physical exercise in cerebral ischemia. Metabolism 68:31–42CrossRefGoogle Scholar
  13. Malla RR, Asimi R, Teli MA, Shaheen F, Bhat MA (2017) Erythropoietin monotherapy in perinatal asphyxia with moderate to severe encephalopathy: a randomized placebo-controlled trial. J Perinatol 37:596–601.  https://doi.org/10.1038/jp.2017.17 CrossRefPubMedGoogle Scholar
  14. Mikrogeorgiou A et al (2017) Dedifferentiated fat cells as a novel source for cell therapy to target neonatal hypoxic-ischemic encephalopathy. Dev Neurosci 39:273–286.  https://doi.org/10.1159/000455836 CrossRefPubMedGoogle Scholar
  15. Ostrowski D, Heinrich R (2018) Alternative erythropoietin receptors in the nervous system. J Clin Med 7:24CrossRefGoogle Scholar
  16. Salakou S et al (2007) Increased Bax/Bcl-2 ratio up-regulates caspase-3 and increases apoptosis in the thymus of patients with myasthenia gravis. In Vivo 21:123–132PubMedGoogle Scholar
  17. Savoia C, Sisalli MJ, Di Renzo G, Annunziato L, Scorziello A (2011) Rosuvastatin-induced neuroprotection in cortical neurons exposed to OGD/reoxygenation is due to nitric oxide inhibition and ERK1/2 pathway activation. Int J Physiol Pathophysiol Pharmacol 3:57–64PubMedPubMedCentralGoogle Scholar
  18. Souvenir R, Flores JJ, Ostrowski RP, Manaenko A, Duris K, Tang J (2014) Erythropoietin inhibits HIF-1alpha expression via upregulation of PHD-2 transcription and translation in an in vitro model of hypoxia-ischemia. Transl Stroke Res 5:118–127.  https://doi.org/10.1007/s12975-013-0312-z CrossRefPubMedGoogle Scholar
  19. Suarez-Mendez S, Tovilla-Zárate CA, Juárez-Rojop IE, Bermúdez-Ocaña DY (2018) Erythropoietin: a potential drug in the management of diabetic neuropathy. Biomed Pharmacother 105:956–961CrossRefGoogle Scholar
  20. Tian T, Zeng J, Zhao G, Zhao W, Gao S, Liu L (2018) Neuroprotective effects of orientin on oxygen-glucose deprivation/reperfusion-induced cell injury in primary culture of rat cortical neurons. Exp Biol Med (Maywood NJ) 243:78–86.  https://doi.org/10.1177/1535370217737983 CrossRefGoogle Scholar
  21. Wu YW et al (2016) High-dose erythropoietin and hypothermia for hypoxic-ischemic encephalopathy: a phase II trial. Pediatrics.  https://doi.org/10.1542/peds.2016-0191 CrossRefPubMedPubMedCentralGoogle Scholar
  22. Xu G, Gong Z, Yu W, Gao L, He S, Qian Z (2007) Increased expression ratio of Bcl-2/Bax is associated with crocin-mediated apoptosis in bovine aortic endothelial cells. Basic Clin Pharmacol Toxicol 100:31–35.  https://doi.org/10.1111/j.1742-7843.2007.00001.x CrossRefPubMedGoogle Scholar
  23. Yan F et al (2016) Erythropoietin improves hypoxic-ischemic encephalopathy in neonatal rats after short-term anoxia by enhancing angiogenesis. Brain Res 1651:104–113.  https://doi.org/10.1016/j.brainres.2016.09.024 CrossRefPubMedGoogle Scholar
  24. Yan X et al (2017) Vanillin protects dopaminergic neurons against inflammation-mediated cell death by inhibiting ERK1/2, p38 and the NF-κB signaling pathway. Int J Mol Sci 18:389CrossRefGoogle Scholar
  25. Yoo S-J et al (2017) The erythropoietin-derived peptide MK-X and erythropoietin have neuroprotective effects against ischemic brain damage. Cell Death Dis 8:e3003CrossRefGoogle Scholar

Copyright information

© King Abdulaziz City for Science and Technology 2019

Authors and Affiliations

  • Wei Si
    • 1
  • Jianyi Wang
    • 1
  • Mei Li
    • 1
  • Hao Qu
    • 1
  • Ran Gu
    • 1
  • Rui Liu
    • 1
  • Lu Wang
    • 1
  • Shirong Li
    • 1
  • Xiao Hu
    • 1
    Email author
  1. 1.Department of NeurologyGuizhou Provincial People’s HospitalGuizhouChina

Personalised recommendations